A series of tetrahydrofuran based compounds with a bicyclic core that provides conformational restriction were synthesized and investigated by radioligand displacement studies and functional 
Introduction
Histamine is a biogenic amine that mediates its multiple physiological effects by the interaction with four known histamine receptor (HR) subtypes, termed H 1 R, H 2 R, H 3 R and H 4 R, all belonging to rhodopsin-like family A of G-protein-coupled receptors (GPCRs). 1 Activation of the H 1 R has long been known to be associated with allergic conditions. 1a,2 Antagonists of this receptor subtype ( popularly referred to as antihistamines) are used as anti-allergic drugs since the 1940s. 2 The H 2 R plays a pivotal role in gastric acid secretion. 3 H 2 R antagonists became blockbuster drugs for the treatment of gastric and duodenal ulcer and gastroesophagal reflux disease. The histamine H 3 R is located predominantly in the central nervous system (CNS) and acts both as a presynaptic autoreceptor 4 modulating histamine release and as an inhibitory heteroreceptor 5 regulating the release of multiple neurotransmitters, such as acetylcholine, 6 dopamine, 7 noradrenaline 8 and serotonin. 9 H 3 R antagonists are being investigated as potential drugs for therapeutic applications against a variety of CNS disorders such as Alzheimer's disease, attention-deficit/hyperactivity disorder (ADHD), epilepsy, migraine, narcolepsy, obesity, schizophrenia and depression. 10 Recently, the H 3 R antagonist pitolisant (tiprolisant) has been introduced as an orphan drug for the treatment of narcolepsy. 11 In the years 2000 and 2001, the H 4 R was identified and cloned independently by several research groups. 12 The H 4 R is mainly expressed in blood forming organs and immunocytes such as mast cells, basophils, eosinophils, monocytes, T-lymphocytes and dendritic cells. 13 It is considered as a new therapeutic target for the modulation of various inflammatory and immunological processes and disorders including bronchial asthma, atopic dermatitis, allergic rhinitis, pruritus, colitis, pain, cancer, rheumatoid arthritis and multiple sclerosis.
14 Due to the significant sequence homology of the H 4 R with the H 3 R (about 40% overall sequence identity and about 60% within the transmembrane domains), 12 many of the reported H 3 R agonists and antagonists showed considerable H 4 R activity as well. 15 However, the development of more selective ligands remains indispensable in order to further elucidate the ( patho-) physiological roles of H 3 R and H 4 R, which might offer new opportunities for the therapy of several diseases.
Since endogenous ligands such as histamine possess flexible structures owing to rotations around single bonds, a reasonable concept to improve potency and subtype selectivity is to restrict the conformational flexibility. 16 The affinity at the respective receptor subtypes increases if such conformationally restricted analogues superimpose the bioactive conformation of the natural ligand. In the case of membrane-bound proteins where structural information is not known precisely, this strategy can be extended by the variation of stereochemistry to explore the right spatial orientation and stereochemical requirements of the pharmacophoric elements in the binding pocket and to refine the models of ligand-receptor interaction. This approach has been successfully applied for the development of selective H 3 R and H 4 R ligands. Fig. 1 shows some examples of histamine analogues comprising rigid carbo-and heterocyclic cores. From a series of cyclopropane-based conformationally constrained histamine analogues with diverse stereochemistry, Shuto et al. identified the "folded" cisanalogue (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane (1, AEIC) to be the most potent agonist at the hH 3 R (K i = 1.3 nM, EC 50 = 10 nM) which had virtually no effect on the H 4 R subtype. 17 Yamatodani et al. synthesized all imifuramine (2) stereoisomers and its corresponding cyanoguanidine analogues and examined the binding affinity and functional activity at the human H 3 and H 4 receptors by in vitro studies. 18 Replacement of the amino group by the cyanoguanidine moiety, which is uncharged at physiological pH, resulted in a decrease in agonistic activity at the hH 3 R. In contrast, the potencies and intrinsic activities increased at the hH 4 R for most isomers. As a result, was identified as the first selective H 4 R agonist. Recently, we explored rigidified cyanoguanidine-type HR ligands having a phenylene or a 1,4-cyclohexylene linker. 19 While the phenylene linker yielded only very weakly active compounds at both hH 3 R and hH 4 R, the less rigid 1,4-cyclohexylene linker gave cis-and trans-configured molecules revealing EC 50 or K B values ≥110 nM at the hH 3 R and hH 4 R. The cis-configured isomers 4 preferred the hH 4 R and were partial agonists, whereas the trans-isomers 5 were antagonists at the hH 4 R. At the hH 3 R the trans-diastereomers 5 were superior to the cis-isomers 4 by a factor of 10. Thus, previous results suggest that the variation of conformational constraints and stereochemical properties is a promising approach to further explore the structure-activity and structure-selectivity relationships of HR ligands.
As part of our efforts to develop further potent and selective H 3 and H 4 receptor ligands that may serve as pharmacological tools and unravel the interactions within the binding pockets, we herein describe the enantioselective synthesis and pharmacological evaluation of potential HR ligands 6-9 containing a modified tetrahydrofuran spacer with a conformationally constrained scaffold and diverse spatial orientations (Scheme 1). The core structure consists of a fused ring system and is formed by an asymmetric cyclopropanation reaction, which gives rise to the bicyclic building block 10. The formation of the imidazole moiety represents a key step in the synthetic route and is realized by the conversion of aldehyde 11 via the TosMIC strategy. Finally, the amino group of 8 and the cyanoguanidino group of 6 are introduced by further functional group interconversions including a Mitsunobu-type Gabriel reaction. In parallel, analogues 9 and 7 with an oxazole moiety as a potential bioisostere are synthesized and pharmacologically characterized. All target compounds are accessible as both enantiomers depending on the choice of the respective chiral ligand in the asymmetric cyclopropanation step.
Results and discussion

Chemistry
In the course of synthesizing various γ-butyrolactone containing natural products 20 we had previously developed the asymmetric cyclopropanation of furan-2-carboxylic acid ester 12 derived from commercially available 2-furoic acid (Scheme 2). 21 The reaction proceeded with ethyl diazoacetate in the presence of catalytic copper(I)-isopropyl bis(oxazoline) with high enantio-and diastereoselectivity to give bicyclic compound 10. The double bond in 10 was hydrogenated accordingly using palladium on charcoal in EtOAc.
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The hydrogenation proceeds via syn-addition exclusively from the less hindered convex face of the bicyclic framework to form 13 as a single stereoisomer after recrystallization. A directed thus highly chemoselective reduction of the methyl ester to alcohol 14, being assisted by the adjacent furan ring oxygen, was followed by a Dess-Martin oxidation to give aldehyde 15. Subsequent base-induced [3 + 2] cycloaddition with p-toluenesulfonylmethyl isocyanide (TosMIC) afforded tosyloxazoline 16 as a mixture of diastereomers. 23 The conversion to the corresponding imidazole 17 by treatment with ammonia according to Horne et al. turned out to be not feasible. 24 Also several Organic & Biomolecular Chemistry Paper of the silylether, oxidation of alcohol 21 by means of DessMartin periodinane afforded aldehyde 22 which underwent cycloaddition with TosMIC. 23 The resulting oxazoline diastereomers 23 were treated with a solution of ammonia in MeOH at elevated temperature in a sealable pressure tube giving rise to the desired imidazole 24 in up to 68% yield. 24 Besides the expected imidazole isomer 24a, epimer 24b was identified as well due to the basic and high temperature conditions applied. Best results (24a : 24b = 5 : 1) were obtained by heating at 95°C, while higher temperatures caused increased epimerization. Following the protocol of Harusawa et al., imidazole 24 was converted to its base-sensitive carbamate-protected derivative 25 using ethyl chloroformate to improve the solubility properties and to facilitate the separation of the epimers at a later stage of the reaction sequence. 26 Cleavage of the benzyl ether to give alcohol 26 was realized by catalytic transfer hydrogenation using palladium hydroxide on carbon and cyclohexene as the hydrogen donor. 27 At this point, separation of the isomers was necessary since the next step provided several side-products, which were otherwise tedious to separate and to characterize. To displace the hydroxyl group of the (3R)-isomer 26a with an amino moiety, a phthaloylimination under Mitsunobu conditions and subsequent hydrazinolysis were performed. 28 By treating 26a with phthalimide in the presence of PPh 3 and DIAD, the desired phthalimide 27a was obtained in low yield. Further ring-opening gave phthalimides 28 as a mixture of epimers due to a cyclopropylcarbinyl-homoallylic rearrangement (Scheme 4). 29 Diene 29 was observed as well but was not separable from the triphenylphosphine oxide byproduct. In order to optimize the conditions for the preparation of the desired phthalimide 27a different conditions were screened using model compound 19. However, the change of the addition order of the reagents, variation in the relative reagent concentrations and different reaction temperatures and solvents did not lead to a significantly improved ratio of products. Cleavage of the phthalimide moiety of compound 27a by means of hydrazinolysis proceeded smoothly with simultaneous removal of the base-sensitive carbamate protection group at the imidazole ring to give the desired target compound amine 8a (Scheme 3). The conversion to the analogous cyanoguanidine-containing compound 6a required two additional steps. First, amine 8a was treated with an excess of dimethyl N-cyanodithioiminocarbonate in MeOH to furnish an isothiourea compound which was then directly converted without purification to the desired cyanoguanidine 6a by adding an ethanolic solution of MeNH 2 .
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The respective (3S)-configured target compounds, amine 8b and cyanoguanidine 6b, were derived from the corresponding (3S)-configured alcohol 26b running through an analogous synthetic pathway via phthalimide 27b. Consequently, the (6R)-configured target molecules, amines 6a and 6b and the cyanoguanidines 8a and 8b could be prepared. Additionally, by employing the (R,R)-isopropyl bis(oxazoline) ligand in the cyclopropanation step, the respective (6S)-enantiomers, amines 8c and 8d and cyanoguanidines 6c and 6d, were accessible.
As a putative bioisostere of the imidazole, an oxazole moiety was introduced by elimination of p-toluene sulfinic acid from tosyloxazoline 16 accompanied by transesterification of the ethyl ester group to give compound 33 (Scheme 5). 23 Subsequent reduction with LiAlH 4 furnished alcohol 34. The hydroxy group was converted into a phthalimide moiety via a Mitsunobu reaction. 28 In comparison to the similar transformation of 26a to 27a described above, the reaction proceeded with the formation of smaller amounts of ring opening products and this with higher yield to the desired 35 (55% vs. 29% for 27a) for reasons that are not clear. Hydrazinolysis gave rise to the amine 9a. The corresponding cyanoguanidine 7a was readily obtained by converting the amino group with dimethyl N-cyanodithioiminocarbonate to isothiourea 36 followed by treatment with MeNH 2 in EtOH. 26 In turn, the application of the enantiomeric isopropyl bis(oxazoline) ligand in the asymmetric cyclopropanation reaction provided access to the enantiomeric target compounds, 9b and 7b, as well.
Pharmacology
All the synthesized target compounds depicted in Fig. 2 In agreement with the findings of Hashimoto et al., the amines 8a-d exhibited significantly stronger binding affinities at the hH 3 R than at the hH 4 R ( Table 1) . At the hH 3 R the (6R)-configured eutomers 8a and 8b showed submicromolar K i values. Both compounds were about 10-fold more potent than their (6S)-configured distomers 8c and 8d. At the hH 4 R, compounds 8a and 8d, having the (3R)-configuration, exhibited weak binding affinities with low micromolar K i values. In contrast to this, the respective (3S)-configured epimers 8b and 8c did not show any significant binding (K i > 10 000 nM) at this receptor subtype. An unambiguous preference for either the folded isomers ((3R,6R)-cis-8a and (3S,6S)-cis-8d) or the extended analogues ((3S,6R)-trans-8b and (3R,6S)-trans-8c) was not observed at both receptor subtypes. As a result, binding affinities for the amines 8a, 8b, 8c and 8d at the hH 3 R were 25, >34, >4 and 3-fold higher than at the hH 4 R subtype, respectively. Additionally, 8a-d were devoid of activity at the hH 1 R and hH 2 R. 8a and 8b were investigated for their functional activity at the hH 3 R. In contrast to imifuramine and its stereoisomers, which were all reported to act as full agonists at the H 3 R, 18 8a and 8b turned out to be almost neutral antagonists with K B values of 181 and 32 nM, respectively. The elongated spacer and the different spatial arrangement of the pharmacophoric elements were tolerated to a certain extent for the conformationally constrained amines compared to Hashimoto's THF-based ligands. At both HR subtypes comparable K i values were determined, especially at the hH 3 R, but the quality of action was different. In contrast, the cyanoguanidines 6a-d turned out to be inactive (K i > 10 000 nM) at all four HR subtypes, notably at the H 4 R. In this case, the orientation of the pharmacophoric elements, provided by the bicyclic core, is detrimental for receptor binding. An increase in hH 4 R affinity by replacement of the amino group with a cyanoguanidino moiety -as observed for the imifuramine based compounds 18 -was not achieved. The synthesized oxazoles 9a, 9b, 7a and 7b were investigated in radioligand binding assays at the hH 1 R and hH 2 R Scheme 5 Reagents and conditions: (a) K 2 CO 3 , MeOH, reflux, 0.5 h, 31%; (b) LAH, THF, 0°C, 0.5 h, 71%; (c) PPh 3 , phthalimide, DIAD, THF, 0°C, 0.5 h, 55%; (d) hydrazine hydrate, EtOH, reflux, 1.5 h, 72%; (e) dimethyl N-cyanodithioiminocarbonate, EtOH, rt, 18 h, quant.; (f ) MeNH 2 in EtOH, rt, 18 h, 90%. 
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Organic & Biomolecular Chemistry subtypes and in functional [ 35 S]GTPγS assays at the hH 3 R and hH 4 R subtypes but did not reveal any activity at all receptor subtypes. Even oxazole 9a, whose imidazole analogue 8a exhibited submicromolar affinities at the hH 3 R, was inactive at the hH 3 R. Thus, in this class of HR ligands, independently from the other structural modifications, the oxazole ring proved to be inappropriate as a bioisostere of an imidazole ring. This is presumably due to a different H-bond donoracceptor interaction pattern and the reduced basicity of the oxazole moiety compared to the imidazole ring.
Conclusion
In conclusion, we have synthesized and pharmacologically characterized a set of bicyclic imifuramine analogues as potential histamine receptor ligands. In the imidazole series, the conformationally constrained amines and cyanoguanidines were obtained in 15 and 17 steps, respectively, starting from commercially available furan-2-carboxylic acid. The oxazole analogues could be realized in 10 and 12 steps, respectively. The synthetic pathways deliver valuable information about the scope and limitations of the rigid bicyclic core in terms of chemical transformations of its substituents. In the case of the imidazole compounds the introduction of the aromatic heterocyles by TosMIC chemistry gave rise to additional epimers. As a result, different isomers with distinct stereochemical orientations could be achieved. Pharmacological investigations at the human HR subtypes revealed affinities of the amines 8 at the hH 3 R in a comparable range as reported for the imifuramine derived stereoisomers, but with different qualities of action. Especially 8b showed high subtype selectivity for the hH 3 R with no affinity for the hH 4 R. In agreement with these findings and in contrast to the cyanoguanidine 3 bearing the tetrahydrofuran moiety, the cyanoguanidines 6 were devoid of activity at the hH 4 R as well. These results suggest that the 2-oxabicyclo[3.1.0]hexane framework used in this study might be a promising scaffold for the hH 3 R selective ligands. Replacement of the imidazole ring by an oxazole substituent as a potential bioisostere led to loss of activities at HR subtypes. Apparently, the H-bond donor and acceptor properties and the basicity of the oxazole ring are inappropriate. These findings contribute to the objective of further elucidating the structural requirements of selective histamine H 3 and H 4 receptor ligands that may help to enable the synthesis of tailored compounds as novel pharmacological tools and potential drugs with the intended quality of action. Ligands concentrations from 1 nM to 1 mM as appropriate to generate saturated concentration/response curves. Compounds showing no effect in this range were referred to as inactive. N gives the number of independent experiments performed in triplicate each. The intrinsic activity (α) of histamine was set to 1.00 and α values of other compounds were referred to this value. The α values of neutral antagonists and inverse agonists were determined at a concentration of 10 μM. The K B values of neutral antagonists were determined in the antagonist mode versus histamine (100 nM) as the agonist.
c Values taken from Igel et al. 30 d Values for hH 3 R and hH 4 R taken from Hashimoto et al.
18 e Measured at a ligand concentration of 100 µM.
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Experimental Chemistry Analytical HPLC analysis was performed with a system from Merck (Darmstadt, Germany) consisting of a L-5000 controller, a 655A-12 pump, a 655A-40 autosampler and a L-4250 UV-VIS detector on a Eurospher-100 C18 column (250 × 4 mm, 5 μm, Knauer, Berlin, Germany) at a flow rate of 0.8 mL min −1 . Mixtures of acetonitrile and 0.05% aq. TFA were used as the mobile phase. Helium degassing was used throughout. Compound purities were calculated as the percentage peak area of the analyzed compound by UV detection at 210 nm. HPLC conditions, retention times (t R ), capacity factors (k′ = (t R − t 0 )/t 0 ) and purities of the synthesized compounds are listed in the ESI. † All reactions were carried out in oven-dried glassware under atmospheric conditions unless otherwise stated. All solvents were dried and distilled prior to use. Thin layer chromatography (TLC) was performed using silica gel 60 F254 aluminium plates (Merck). Eluted plates were visualized using a 254 nm UV lamp and/or by treatment with a suitable stain followed by heating. Column chromatography was performed on silica gel 60 (0.063-0.200 mm, Merck Preparative HPLC was performed at room temperature with a system from Knauer (Berlin, Germany) consisting of two K-1800 pumps, a K-2001 detector (UV detection at 220 nm) and a RP-column (VP Nucleodur 100-5 C18 ec, 250 × 21 mm, 5 μm, Macherey Nagel, Düren, Germany) at a flow rate of 15 mL min Acetonitrile was removed from the eluates under reduced pressure at 45°C prior to lyophilization.
A solution of compound 8a (5.0 mg, 0.028 mmol) and dimethyl N-cyanodithioiminocarbonate (9.9 mg, 0.067 mmol, 2.4 equiv.) in anhydrous MeOH (0.55 mL) was stirred at room temperature for 18 h. Then a 33% solution of MeNH 2 in EtOH (0.52 mL) was added and stirred for 18 h at room temperature. The solvent was evaporated to give a residual oil that was purified by column chromatography (EtOAc- 2625, 1573, 1454, 1414, 1361, 1306, 1177, 1098, 1067, 1028, 980, 912, 841, 632, 540, 497 (14) . To a stirred ice-cooled solution of 13 (2.45 g, 11.4 mmol) in anhydrous THF (45 mL) under a nitrogen atmosphere, a suspension of LAH (260 mg, 6.87 mmol, 0.6 equiv.) in anhydrous THF (5 mL) was added dropwise within 10 min. The reaction mixture was stirred for 45 min at 0°C. After dropwise addition of water (260 µL) the mixture was stirred for another 30 min. Then a 15% aqueous NaOH solution (260 µL) was added, followed by water (780 µL). The mixture was warmed to room temperature, treated with MgSO 4 and filtered through a Celite pad. The solvent was evaporated under reduced pressure. The crude product was (15) . Dess-Martin periodinane (4.24 g, 10.0 mmol, 1.05 equiv.) was added to a solution of alcohol 14 (1.77 g, 9.52 mmol) in DCM (95 mL) at room temperature and stirred for 1 h. After completion the reaction was quenched with a mixture of saturated aqueous Na 2 S 2 O 3 solution (50 mL) and saturated aqueous NaHCO 3 solution (50 mL). The mixture was stirred for 15 min; afterwards the organic layer was separated and the aqueous layer was extracted with DCM (2 × 50 mL). The combined organic layers were washed with brine (1 × 50 mL), dried over MgSO 4 2984 , 1712 , 1451 , 1411 , 1385 , 1323 , 1298 , 1273 , 1177 , 1107 , 1051 , 1035 MS (CI) : m/z (%) = 185.0 (15) 2936, 1716, 1618, 1453, 1408, 1387, 1306, 1177, 1149, 1108, 1086, 1075, 975, 934, 852, 813, 707, 668 (18) . To a stirred solution of alcohol 14 (2.53 g, 13.6 mmol) in DCM (45 mL) under a nitrogen atmosphere, anhydrous NEt 3 (2.8 mL, 20 mmol, 1.5 equiv.), TBSCl (2.48 g, 16.5 mmol, 1.2 equiv.) and DMAP (83 mg, 0.68 mmol, 0.05 equiv.) were added successively. The reaction mixture was stirred for 18 h at room temperature and then quenched with a saturated aqueous NH 4 Cl solution (40 mL). The layers were separated and the aqueous layer was extracted with DCM (2 × 20 mL). The combined organic phases were dried over MgSO 4 , filtered and concentrated in vacuo. Purification by column chromatography (PE-EtOAc 5 : 1) afforded compound 18 (3.88 g, 12.9 mmol, 95%) as a colorless oil. 2858, 1720, 1463, 1408, 1309, 1256, 1176, 1112, 1096, 1054, 979, 839, 778 Preparation of ((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)-methyl)-2-oxabicyclo[3.1.0]hexan-6-yl)-methanol (19) . To a
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Organic & Biomolecular Chemistry stirred ice-cooled solution of 18 (3.88 g, 12.9 mmol) in anhydrous THF (50 mL) under a nitrogen atmosphere, a suspension of LAH (412 mg, 10.9 mmol, 0.84 equiv.) in anhydrous THF (5 mL) was added dropwise within 10 min. The reaction mixture was stirred for 45 min at 0°C. After dropwise addition of water (0.41 mL) the mixture was stirred for another 30 min. Then a 15% aqueous NaOH solution (0.41 mL) was added, followed by water (1.24 mL). The mixture was warmed to room temperature, treated with MgSO 4 and filtered through a Celite pad. The solvent was evaporated under reduced pressure. The crude product was purified by column chromatography (PE-EtOAc 3 : 1 then 1 : 1) to obtain compound 19 (3.17 g, 12.3 mmol, 95%) as a colorless oil. 
Preparation of (((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)methoxy)(tert-butyl)-dimethylsilane (20).
To a solution of alcohol 19 (1.00 g, 3.87 mmol) in anhydrous DMF (25 mL), NaH (309 mg, 60 wt% in mineral oil, 7.74 mmol, 2.0 equiv.) was added in one portion at 0°C under a nitrogen atmosphere. The resulting suspension was stirred at 0°C for 10 min, and then benzyl bromide (919 µL, 7.74 mmol, 2.0 equiv.) was added dropwise at 0°C. The mixture was allowed to warm to room temperature and stirred for 2 h. MeOH (5 mL) was added carefully to quench the reaction. The solvent was evaporated under reduced pressure. The residue was diluted in DCM and washed with a saturated aqueous NH 4 Cl solution (20 mL). The aqueous phase was extracted with DCM (3 × 20 mL). The organic layers were combined, dried over MgSO 4 and concentrated in vacuo. The resulting residue was purified by column chromatography (PE-EtOAc 9 : 1) to obtain compound 20 (1.14 g, 3.28 mmol, 85%) as a colorless oil. 2932 , 2858 , 1461 , 1380 , 1254 , 1182 , 1132 , 1091 , 1009 MS (ESI) : m/z (%) = 241. O (4.11 mg, 13 .0 mmol, 1.5 equiv.) in anhydrous THF (30 mL) was added and stirred for 13 h at room temperature. After evaporating the solvent the crude product was purified by column chromatography (EtOAc) to give 21 (1.94 mg, 8.28 mmol, 95%) as a colorless oil. 3027, 2924, 2862, 1497, 1454, 1414, 1360, 1180, 1087, 1071, 1028, 987, 844, 810, 739, 698, 614 Preparation of (1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexane-3-carbaldehyde (22) . To a stirred solution of alcohol 21 (4.35 g, 18.6 mmol) in DCM (150 mL) was added in one portion Dess-Martin periodinane (8.66 g, 20.4 mmol, 1.1 equiv.) at room temperature. After 2 h, a saturated aqueous NaHCO 3 (60 mL) and a saturated aqueous Na 2 S 2 O 3 (60 mL) were added. The mixture was stirred for another 15 min. After completion the reaction was quenched with a mixture of saturated aqueous Na 2 S 2 O 3 solution (60 mL) and saturated aqueous NaHCO 3 solution (60 mL). The mixture was stirred for 15 min, then the organic layer was separated and the aqueous layer was extracted with DCM (2 × 50 mL). The combined organic layers were washed with brine (1 × 50 mL), dried over MgSO 4 and evaporated in vacuo. Purification by column chromatography (PE-EtOAc 1 : 1) afforded compound 22 (3.87 g, 16.7 -4-tosyl-4,5-dihydro-oxazole (23) . Finely powdered NaCN (28 mg, 0.57 mmol, 0.22 equiv.) was added in one portion to a stirred solution of TosMIC (555 mg, 2.84 mmol, 1.1 equiv.) and aldehyde 22 (600 mg, 2.58 mmol) in anhydrous EtOH (25 mL) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred for 2 h. The solvent was evaporated under reduced pressure. The residue was dissolved in CHCl 3 (30 mL) and washed with a saturated aqueous NaHCO 3 solution (30 mL). The aqueous layer was extracted with CHCl 3 (2 × 15 mL) and the combined organic layers were dried over MgSO 4 , filtered and concentrated in vacuo. Purification by column chromatography (PE-EtOAc 1 : 1) afforded a 3 : 2 diastereomeric mixture of compound 23 (854 mg, 2.00 mmol, 77%) as yellowish foam.
Major: R f = 0.41 (PE-EtOAc 1 : 1); 1 H-NMR (300 MHz, CDCl 3 ): δ H = 7.81 (d, J = 8.3 Hz, 2H), 2H), 5H), 1H), 1H), 1H), 1H), 2H), 3.79 (dd, J = 6.2, 0.9 Hz, 1H), 3.31 (dd, J = 10.5, 6.5 Hz, 1H), 3.11 (dd, J = 10.5, 7.3 Hz, 1H) (d, J = 8.3 Hz, 2H), 2H), 5H), 1H), 4.98 (dd, J = 6.2, 1.7 Hz, 1H), 4.84 (dd, J = 6.2, 3.4 Hz, 1H), 1H), 2H), 3.76 (dd, J = 6.3, 0.8 Hz, 1H), 3.26 (dd, J = 10.5, 6.8 Hz, 1H) 2948, 2861, 1616, 1597, 1486, 1455, 1362, 1319, 1304, 1292, 1148, 1108, 1086, 1071, 1028, 939, 848, 813, 739, 700, 664, 651, 587, 533 . Preparation of 5-((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo [3.1.0] hexan-3-yl)-1H-imidazole (24a) and 5-((1S,3S ,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole (24b). In a sealable pressure tube, oxazoline 23 (1.70 g, 3. 98 mmol) and a saturated solution of NH 3 in anhydrous MeOH (40 mL, 70 equiv.) were heated at 95°C for 16 h. Within this time the solution turned red. After cooling, the solvent was removed under reduced pressure. The residue was purified by column chromatography (DCMsaturated NH 3 in MeOH 9 : 1) to give a 5 : 1 epimeric mixture of compounds 24a and 24b (726 mg, 2.69 mmol, 68%) as a colorless oil.
24a: R f = 0.22 (br), 2936 , 2858 , 1716 , 1670 , 1496 , 1453 , 1362 , 1313 , 1273 , 1087 , 1071 , 1027 MS (ESI) : m/z (%) = 271.0 (100 (623 µL, 7.72 mmol, 1.9 equiv.) and DMAP (79 mg, 0.65 mmol, 0.16 equiv.) in benzene (80 mL) was stirred for 10 min at 50°C. After the addition of water (5 mL), the solvent was evaporated. A saturated aqueous NH 4 Cl solution (50 mL) was added and extracted with DCM (3 × 25 mL). The extract was washed with brine, dried over MgSO 4 , filtered and concentrated in vacuo. The residual oil was purified by column chromatography (PE-EtOAc 1 : 1) to give a 3 : 1 epimeric mixture of compounds 25a and 25b (1.01 g, 2.95 mmol, 73%) as a colorless oil.
25a: R f = 0.26 (PE- 2859, 1759, 1482, 1454, 1409, 1388, 1336, 1252, 1207, 1093, 1069, 1019, 843, 769, 740, 699, 607 2982, 2943, 2876, 1758, 1489, 1409, 1336, 1253, 1176, 1103, 1068, 1018, 847, 768, 606 DIAD (211 mg, 0.98 mmol, 1.5 equiv. ) was added to a solution of PPh 3 (257 mg, 0.98 mmol, 1.5 equiv.) in anhydrous THF (7 mL) at room temperature under a nitrogen atmosphere. After stirring for 10 min phthalimide (144 mg, 0.98 mmol, 1.5 equiv.) was added and stirred for another 10 min. After addition of alcohol 26a (165 mg, 0.65 mmol) in THF the reaction mixture was stirred overnight. The solvent was evaporated under reduced pressure. The residue was purified by column chromatography (PE-EtOAc 5 : 1 to EtOAc) to obtain 28a (126 mg, 0.33 mmol, 51%), 28b (25 mg, 0.07 mmol, 10%) and 27a (72 mg, 0.19 mmol, 29%) as colorless oils.
28a: R f = 0.37 ( , 2927, 2853, 1760, 1716, 1468, 1410, 1367, 1332, 1252, 1210, 1084, 1019 977, 919, 891, 845, 769, 736, 721, 655, 611, 531 2925, 1762, 1720, 1468, 1410, 1364, 1326, 1258, 1228, 1113, 1090, 1018, 901, 838, 792, 770, 722, 604, 530 (dd, J = 5.5, 3.0 Hz, 2H), 7.70 (dd, J = 5.5, 3.0 Hz, 2H), 7.24 (t, J = 1.0 Hz, 1H), 5.36 (t, J = 7.7 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 4.05 (dd, J = 6.2, 0.9 Hz, 1H), 3.51 (dd, J = 14.3, 7.1 Hz, 1H), 3.38 (dd, J = 14.3, 8.2 Hz, 1H), 2.59 (ddd, J = 12.9, 8.4, 7. 2954 , 1716 , 1507 , 1440 , 1394 , 1311 , 1274 , 1198 , 1171 , 1107 , 1070 MS (EI) : m/z (%) = 95.0 (100), 180. Preparation of (1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo-[3.1.0]hexan-6-yl)methanol (34). To a stirred ice-cooled solution of oxazole 33 (65 mg, 0.31 mmol) in anhydrous THF (3 mL) under a nitrogen atmosphere, LAH (9.3 mg, 0.25 mmol, 0.8 equiv.) was added in small portions within 5 min. The reaction mixture was stirred for 30 min at 0°C. After addition of water (10 µL) the mixture was stirred for another 30 min. Then a 15% aqueous NaOH solution (10 µL) was added followed by water (30 µL) . The mixture was warmed to room temperature, treated with MgSO 4 and filtered through a Celite pad. The solvent was evaporated under reduced pressure. The crude product was purified by column chromatography (EtOAc) to obtain compound 34 (40 mg, 0.22 mmol, 71%) as a colorless solid. Mp = 95°C; R f = 0.19 (EtOAc); [α] 
